Creative Lead (ACD, Copy)
Currently leading the initiative to reposition NUZYRA as the next-generation tetracycline that’s appropriate for patients with serious infections and comorbid renal disease.
Included are original concepts and their evolution, including materials we pushed live in May 2025.